Breaking News Instant updates and real-time market news.

AZRX

AzurRx BioPharma

$1.54

-0.16 (-9.41%)

08:17
12/19/18
12/19
08:17
12/19/18
08:17

AzurRx BioPharma initiates Phase 2 OPTION study

AzurRx BioPharma announced that it has initiated the company's Phase II OPTION study to investigate MS1819-SD in cystic fibrosis, or CF, patients with exocrine pancreatic insufficiency, or EPI. The Phase II multi-center study is designed to investigate the safety, tolerability and efficacy of MS1819-SD in a head-to-head comparison against the current porcine enzyme replacement therapy standard of care. Planned enrollment is expected to include approximately 30 CF patients, with study completion anticipated in 2019. The study has a six-week non-inferiority, coefficient of fat absorption, or CFA, primary endpoint comparing MS1819-SD to porcine enzyme replacement therapy in patients with exocrine pancreatic insufficiency due to cystic fibrosis.

AZRX AzurRx BioPharma
$1.54

-0.16 (-9.41%)

10/17/18
10/17/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ulta Beauty (ULTA) initiated with a Buy at Argus. 2. Principal Financial (PFG) initiated with a Hold at Deutsche Bank. 3. MongoDB (MDB) initiated with an Outperform at Oppenheimer. 4. Simply Good Foods (SMPl) initiated with a Buy at Buckingham. 5. AzurRx BioPharma (AZRX) initiated with an Outperform at Oppenheimer. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/17/18
OPCO
10/17/18
INITIATION
Target $6
OPCO
Outperform
AzurRx BioPharma initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leland Gershell started AzurRx BioPharma with an Outperform rating and $6 price target. The company's lead candidate MS1819 is a next-generation enzyme replacement for exocrine pancreatic insufficiency, a condition responsible for significant morbidity among the chronic pancreatitis and cystic fibrosis populations, Gershell tells investors in a research note. The analyst believes MS1819's advantages to current products could enable it to become the exocrine pancreatic insufficiency treatment of choice and forecasts 2027 sales of $266M following a 2022 launch.
09/25/18
HCWC
09/25/18
NO CHANGE
Target $8
HCWC
Buy
AzurRx BioPharma price target raised to $8 from $6 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for AzurRx BioPharma to $8 after the company announced that the Phase 2a trial of MS1819 in chronic pancreatitis patients with exocrine pancreatic insufficiency met both primary and secondary endpoints. Importantly, the efficacy demonstrated by MS1819 is comparable to that of the porcine-derived pancrelipase currently on the market, such as Creon, Selvaraju tells investors in a research note. He views the data as "very encouraging" and reiterates a Buy rating on AzurRx.
06/01/18
HCWC
06/01/18
NO CHANGE
HCWC
Buy
AzurRx hiring experienced CMO adds validation to MS1819, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju noted that AzurRx BioPharma (AZRX) hired Dr. James Pennington, who was previously Chief Medical Officer and later Senior Clinical Fellow at Anthera Pharmaceuticals (ANTH), as the company's CMO. The fact that an experience CMO such as Dr. Pennington agreed to join AzurRx adds incremental validation to MS1819, the company's candidate for EPI associated with chronic pancreatitis and cystic fibrosis, said Selvaraju, who keeps a Buy rating on AzurRx shares.

TODAY'S FREE FLY STORIES

BBDC

Barings BDC

$10.11

-0.03 (-0.30%)

07:17
10/23/19
10/23
07:17
10/23/19
07:17
Initiation
Barings BDC initiated  »

Barings BDC initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

FDUS

Fidus Investment

$14.63

(0.00%)

07:17
10/23/19
10/23
07:17
10/23/19
07:17
Initiation
Fidus Investment initiated  »

Fidus Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

WHF

WhiteHorse Finance

$13.97

0.12 (0.87%)

07:16
10/23/19
10/23
07:16
10/23/19
07:16
Initiation
WhiteHorse Finance initiated  »

WhiteHorse Finance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

SLGN

Silgan Holdings

$31.05

-0.02 (-0.06%)

07:16
10/23/19
10/23
07:16
10/23/19
07:16
Earnings
Silgan Holdings tightens FY19 adj. EPS view to $2.12-$2.17 from $2.10-$2.20 

Consensus $2.18.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SGC

Superior Uniform

$15.57

-0.09 (-0.57%)

07:16
10/23/19
10/23
07:16
10/23/19
07:16
Earnings
Superior Uniform reports Q3 EPS 26c, one est. 25c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

LAD

Lithia Motors

$130.17

-5.24 (-3.87%)

07:15
10/23/19
10/23
07:15
10/23/19
07:15
Earnings
Lithia Motors reports Q3 EPS $3.39, consensus $3.09 »

Reports Q3 revenue $3.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

OPRT

Oportun Financial

$16.25

0.23 (1.44%)

07:15
10/23/19
10/23
07:15
10/23/19
07:15
Initiation
Oportun Financial initiated  »

Oportun Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLGN

Silgan Holdings

$31.05

-0.02 (-0.06%)

07:14
10/23/19
10/23
07:14
10/23/19
07:14
Earnings
Breaking Earnings news story on Silgan Holdings »

Silgan Holdings sees Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

PHM

PulteGroup

$39.44

1.2 (3.14%)

07:14
10/23/19
10/23
07:14
10/23/19
07:14
Recommendations
PulteGroup analyst commentary  »

PulteGroup price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 07

    Nov

MICT

MICT, Inc.

$0.41

-0.0558 (-12.08%)

07:14
10/23/19
10/23
07:14
10/23/19
07:14
Hot Stocks
MICT, Inc. receives $1.2M order for on-board computer »

MICT announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTRH

Waitr Holdings

$0.58

0.0105 (1.85%)

07:14
10/23/19
10/23
07:14
10/23/19
07:14
Downgrade
Waitr Holdings rating change  »

Waitr Holdings downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

ALKS

Alkermes

$18.42

0.01 (0.05%)

07:14
10/23/19
10/23
07:14
10/23/19
07:14
Hot Stocks
Alkermes sees ALKS 3831 NDA for schizophrenia, bipolar I this quarter »

Alkermes CEO Richard Pops…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

SLGN

Silgan Holdings

$31.05

-0.02 (-0.06%)

07:14
10/23/19
10/23
07:14
10/23/19
07:14
Earnings
Silgan Holdings reports Q3 adj. EPS 76c, consensus 76c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

AKCA

Akcea Therapeutics

$18.09

-0.85 (-4.49%)

, IONS

Ionis Pharmaceuticals

$54.73

-0.53 (-0.96%)

07:13
10/23/19
10/23
07:13
10/23/19
07:13
Hot Stocks
Akcea Therapeutics promotes Kyle Jenne to CCO »

Akcea Therapeutics…

AKCA

Akcea Therapeutics

$18.09

-0.85 (-4.49%)

IONS

Ionis Pharmaceuticals

$54.73

-0.53 (-0.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 06

    Nov

  • 07

    Dec

CLF

Cleveland-Cliffs

$7.15

0.16 (2.29%)

07:12
10/23/19
10/23
07:12
10/23/19
07:12
Hot Stocks
Cleveland-Cliffs sees FY19 sales volume 19.5M long tons »

Sees FY19 production…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

EVGN

Evogene

$1.72

(0.00%)

07:11
10/23/19
10/23
07:11
10/23/19
07:11
Hot Stocks
Evogene subsidiary Biomica partners with Weizmann Institute »

Evogene subsidiary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

WGO

Winnebago

$42.79

0.47 (1.11%)

07:11
10/23/19
10/23
07:11
10/23/19
07:11
Hot Stocks
Winnebago CEO sees 'significant runway' for team, overall business »

CEO Michael Happe said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

SNV

Synovus

$34.07

-2.225 (-6.13%)

07:11
10/23/19
10/23
07:11
10/23/19
07:11
Downgrade
Synovus rating change  »

Synovus downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CMG

Chipotle

$831.69

-20.195 (-2.37%)

07:10
10/23/19
10/23
07:10
10/23/19
07:10
Recommendations
Chipotle analyst commentary  »

Chipotle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

BIIB

Biogen

$281.96

58.39 (26.12%)

07:09
10/23/19
10/23
07:09
10/23/19
07:09
Upgrade
Biogen rating change  »

Biogen upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WGO

Winnebago

$42.79

0.47 (1.11%)

07:09
10/23/19
10/23
07:09
10/23/19
07:09
Earnings
Winnebago reports Q4 EPS $1.01, consensus $1.00 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

HAL

Halliburton

07:09
10/23/19
10/23
07:09
10/23/19
07:09
Downgrade
Halliburton rating change  »

Halliburton downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

ETON

Eton Pharmaceuticals

$6.43

0.765 (13.52%)

07:09
10/23/19
10/23
07:09
10/23/19
07:09
Recommendations
Eton Pharmaceuticals analyst commentary  »

Eton Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Mar

DPZ

Domino's Pizza

$258.95

1.56 (0.61%)

07:08
10/23/19
10/23
07:08
10/23/19
07:08
Initiation
Domino's Pizza initiated  »

Domino's Pizza…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

  • 13

    Nov

  • 11

    Dec

CLF

Cleveland-Cliffs

$7.15

0.16 (2.29%)

07:08
10/23/19
10/23
07:08
10/23/19
07:08
Earnings
Cleveland-Cliffs reports Q3 EPS 33c, consensus 24c »

Reports Q3 revenue $556M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.